Home » EMEA Lays Out Requirements for Trials of GERD Drugs
EMEA Lays Out Requirements for Trials of GERD Drugs
January 20, 2010
Sponsors testing gastroesophageal reflux disease (GERD) treatments for reflux esophagitis in Phase III trials should use a primary endpoint of complete
healing of mucosal breaks, the European Medicines Agency (EMEA) recommends in a new guideline.